NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
27 trialsNCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03043950 2024-04-24
VALIDATE
iOMEDICO AG
Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT02923921 2020-10-19
Sequoia
Eli Lilly and Company
Phase 3 Completed
NCT00724503 2019-03-26
SIRFLOX
Sirtex Medical
Phase NA Completed
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT03362684 2017-12-05
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
IntegraGen SA
Phase 3 Completed
NCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT00440310 2015-08-25
Phase 3 Trial of Litxâ„¢ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Light Sciences Oncology
Phase 3 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00778830 2015-05-14
APEC
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00349336 2012-09-18
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed
NCT00479583 2011-11-30
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
Bristol-Myers Squibb
Phase 1 Completed
NCT00866944 2011-11-11
MT201-204
Amgen Research (Munich) GmbH
Phase 2 Completed